The Food and Drug Administration June 15 approved Symjepi, an epinephrine injection developed by Adamis Pharmaceuticals Corp.
Here are five things to know.
- Symjepi is a single-dose prefilled syringe of epinephrine intended to treat emergency allergic reactions, including anaphylaxis.
- The injection will directly compete with Mylan's EpiPen, which holds a majority of the epinihprine injection market.
- Adamis has not disclosed an official price for Symjepi. The drugmaker hopes to sell a two-pack of Symjepi for cheaper than Mylan's generic EpiPens, which cost $300 for a pack of two, reports CBS News.
- The drugmaker plans to launch the product in the second half of 2017.
- Adamis will also submit a new drug application to the FDA for a lower-dose version of Symjepi, which will compete with Mylan's EpiPen Jr.
More articles on supply chain:
Nevada governor signs drug price transparency legislation: 5 things to know
Hospira recalls several injectables over sterility concerns
Trump administration readies executive order addressing drug prices